

Anti-CD20 (Ibritumomab), Humanized Antibody

02/21

CATALOG NO.: A2291-50 (50 µg)
 A2291-100 (100 µg)

BACKGROUND DESCRIPTION: This research-grade biosimilar is a monoclonal antibody with a human IgG2A backbone fused to the antigen-binding domain and targets CD20, a surface antigen found on B lymphocytes. Binding of the CD20 surface antigen has been shown to induce apoptosis in B lymphocytes *in vitro*. The humanized anti-CD20 antibody, in concert with a carrier, acts as a delivery system for radioimmunotherapy against B cell lymphoma.

ALTERNATE NAMES: B1; S7; Bp35; CD20; CVID5; MS4A1; LEU-16

ANTIBODY TYPE: Monoclonal

HOST/ISOTYPE: Recombinant / IgG2A

SOURCE: CHO cells

IMMUNOGEN: Human CD20

CAS NUMBER: 206181-63-7

FORM: Liquid

FORMULATION: In PBS, pH 7.5

SPECIES REACTIVITY: Human

STORAGE CONDITIONS: Store at -80 °C. Avoid repeated freeze-thaw cycles

This information is only intended as a guide. The optimal dilutions must be determined by the user

RELATED PRODUCTS:

Anti-EGFR (Matuzumab), Human IgG1 Antibody (Cat. No. A1090)
 Anti-CD20 / MS4A1 Antibody (SPM618) (Cat. No. A1480)
 Anti-CD20 Antibody (2F4) (Cat. No. A1385)
 Anti-CD20 (Obinutuzumab), Humanized Antibody (Cat. No. A2180)
 Anti-CD20 (Rituximab), Chimeric Antibody (Cat. No. A1049)
 Anti-HER2 (Pertuzumab), Humanized Antibody (Cat. No. A2111)
 Anti-HER2 Humanized Antibody (Cat. No. A1046)

FOR RESEARCH USE ONLY! Not to be used on humans.